Syntara Ltd Asset Resilience Ratio
Syntara Ltd asset resilience ratio. Syntara Ltd (SNT) has an Asset Resilience Ratio of 85.55% as of June 2005. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Syntara Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Syntara Ltd (2005–2023)
Asset resilience ratio of Syntara Ltd from 2005 to 2023. This chart shows how Syntara Ltd's Asset Resilience Ratio has changed over time. Read debt load of Syntara Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Syntara Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Syntara Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$32.45 Million | 85.55% |
| Total Liquid Assets | AU$32.45 Million | 85.55% |
Asset Resilience Insights
- Very High Liquidity: Syntara Ltd maintains exceptional liquid asset reserves at 85.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Syntara Ltd Industry Peers by Asset Resilience Ratio
Compare Syntara Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Syntara Ltd Asset Resilience Ratio by Year (2005–2023)
Syntara Ltd asset resilience ratio by year from 2005 to 2023. The table below shows the annual Asset Resilience Ratio data for Syntara Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 36.40% | AU$8.75 Million ≈ $6.19 Million |
AU$24.03 Million ≈ $17.00 Million |
+2.67pp |
| 2022-06-30 | 33.73% | AU$8.49 Million ≈ $6.01 Million |
AU$25.19 Million ≈ $17.82 Million |
-51.82pp |
| 2005-06-30 | 85.55% | AU$32.45 Million ≈ $22.96 Million |
AU$37.94 Million ≈ $26.84 Million |
-- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more